Boston, United States
Manus Bio is a bioalternatives scale-up platform founded in 2011 with the slogan "Accelerating the Transition to BioAlternatives." The company operates in the Biopharma, Biotechnology, and Food and Beverage industries from its headquarters in the United States.
Recognized as the world’s leading platform in its field, Manus Bio collaborates with companies across industries and value chains to expedite the transition to bioalternatives - improved performing and more sustainable versions of complex molecules that were traditionally sourced from plants, animals, or fossil fuels. The platform's proven efficacy in bridging the Valley of Death between lab and manufacturing is heralded for enhancing efficiency and reliability, thereby delivering the benefits of synthetic biology today.
Most recently, Manus Bio secured a significant $2.00M grant investment on 31 August 2022, with the backing of the Bill & Melinda Gates Foundation, further fortifying its position in the industry and marking a noteworthy development in its growth trajectory.
